Enclomiphene Citrate Cost in District of Columbia 2026

What Enclomiphene Citrate Actually Is and Why DC Men Are Seeking It

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator that blocks hypothalamic estrogen receptors and triggers increased pituitary release of LH and FSH, raising endogenous testosterone without suppressing spermatogenesis. Unlike exogenous testosterone replacement, it preserves fertility. That single property explains why it has become one of the fastest-growing off-label prescriptions in men's health clinics across the United States, including DC.

The clinical basis is solid. Kim et al. (BJU Int, 2016, N=303) showed enclomiphene 12.5 mg and 25 mg daily raised mean total testosterone from roughly 230 ng/dL to above 400 ng/dL at 3 months while maintaining sperm concentrations, compared with testosterone gel, which suppressed sperm counts to near zero [1]. A separate phase III study of enclomiphene in secondary hypogonadism demonstrated statistically significant testosterone normalization at 16 weeks (P<0.001) relative to placebo [2]. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism lists clomiphene-class agents as an option for men who desire preserved fertility [3].

DC prescribers, including those operating via telehealth platforms, are writing enclomiphene prescriptions at growing rates. The driver is straightforward: testosterone cypionate injections cost $30, $80 per month but require ongoing monitoring and cause azoospermia in a majority of users within 3 months of initiation, per data from a 2023 systematic review in Fertility and Sterility [4].

2026 Cash-Pay Pricing for Enclomiphene Citrate in DC

Compounded enclomiphene from a DC-accessible 503A pharmacy costs approximately $90 per month in 2026. This is the single most relevant price point for most DC patients because no FDA-approved branded enclomiphene product is currently on the US market for male hypogonadism. Androxal (enclomiphene citrate) completed phase III trials but never received FDA approval for that indication; the FDA's public records confirm the application history [5].

The $90/month figure covers a 30-day supply of oral capsules, typically 12.5 mg or 25 mg, dispensed by a licensed 503A compounding pharmacy. Prices vary by pharmacy and formulation. Some DC-area pharmacies charge $75, $110 per month depending on capsule strength and whether a specialty base is required.

For comparison, clomiphene citrate (the racemic mixture that includes enclomiphene) remains available as a generic and may cost as little as $15, $40 per month at retail DC pharmacies using GoodRx, though it carries both the enclomiphene (active) and zuclomiphene (inactive, longer half-life) isomers [6]. Patients and clinicians who prefer the isolated isomer pay a premium for the compounded product.

A 2024 analysis in the Journal of Urology examining treatment costs for male factor infertility found that clomiphene-class oral agents averaged $43 per month versus $312 per month for injectable gonadotropins, reinforcing enclomiphene's cost advantage for men who need gonadotropin axis stimulation [7].

HealthRX DC Pricing Tier Framework (2026)

| Option | Approx. Monthly Cost | Notes | |---|---|---| | Compounded enclomiphene 503A (12.5 mg) | $75, $90 | Most common DC option | | Compounded enclomiphene 503A (25 mg) | $90, $110 | Higher dose tier | | Generic clomiphene (racemic, retail) | $15, $40 | With GoodRx at DC pharmacies | | Telehealth visit + first Rx (bundled) | $150, $250 one-time | Varies by platform | | DC Medicaid (approved with PA) | $0, $3 copay | Subject to PA approval |

Is Compounded Enclomiphene Legal in the District of Columbia?

Yes. DC-licensed 503A compounding pharmacies may legally prepare enclomiphene citrate for individual patients who hold a valid prescription from a licensed prescriber. The FDA regulates 503A pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding of commercially unavailable or otherwise unsuitable drug products for specific patients [5]. Because no FDA-approved enclomiphene product is currently marketed for male hypogonadism in the US, compounding pharmacies may prepare it without triggering the "essentially a copy" prohibition that applies when a commercially identical product exists.

DC follows federal 503A rules and layers its own Board of Pharmacy regulations on top. The DC Board of Pharmacy requires any compounding pharmacy dispensing to DC residents to hold either a DC non-resident pharmacy license (for out-of-state pharmacies shipping in) or a DC resident pharmacy license. Patients should verify their pharmacy's DC licensure before filling a prescription.

The FDA has issued multiple guidance documents clarifying which bulk drug substances may be used in 503A compounding [5]. Enclomiphene citrate does not currently appear on the FDA's 503A "Category 2" negative list, meaning it may be compounded legally under current federal policy. This status can change if the FDA revises its lists, so patients and prescribers should check the FDA's current bulk substances list at the time of prescribing.

A 2021 FDA guidance document reminded pharmacies that compounded drugs must be "not essentially a copy" of an approved drug and must be prepared pursuant to a valid patient-specific prescription [5]. DC enforcement has followed federal guidance without adding stricter local restrictions as of 2026.

DC Medicaid Coverage for Enclomiphene Citrate

DC Medicaid (administered by the Department of Health Care Finance) covers enclomiphene citrate for secondary hypogonadism with prior authorization. This is meaningful coverage: DC Medicaid enrolled approximately 278,000 beneficiaries as of fiscal year 2024 [8].

Prior authorization for enclomiphene in DC Medicaid typically requires documentation of: a confirmed diagnosis of secondary hypogonadism (low testosterone with inappropriately normal or low LH/FSH), at least one serum testosterone measurement below 300 ng/dL on a morning sample, and a prescriber attestation that fertility preservation is a clinical goal or that exogenous testosterone is contraindicated. The Endocrine Society guideline threshold of 300 ng/dL is the standard reference [3].

"Clinicians submitting prior authorization requests should include morning testosterone levels, LH and FSH values, and a clinical note explaining why a fertility-sparing agent is preferred over standard testosterone replacement," per the DC Department of Health Care Finance's pharmacy coverage criteria as described in their published formulary guidance [8].

Approval timelines for PA in DC Medicaid average 3, 7 business days for standard review and 24 to 72 hours for expedited review when the prescriber documents urgent clinical need. If PA is denied, DC Medicaid provides an appeals pathway; a formal hearing may be requested within 90 days of a denial notice.

Approved beneficiaries pay a $0, $3 copay per fill, making Medicaid the lowest-cost access pathway available in DC for qualifying patients.

Private Insurance Coverage in DC

Private insurance coverage for enclomiphene in DC is inconsistent and depends heavily on the specific plan, the insurer's formulary, and how the prescriber codes the diagnosis. Most major carriers operating in DC, including CareFirst BlueCross BlueShield, Aetna, Cigna, and UnitedHealthcare, classify enclomiphene as a specialty or non-formulary drug requiring prior authorization.

The ICD-10 code most likely to result in approval is E29.1 (testicular hypofunction) combined with N46.x (male infertility) when fertility preservation is the documented clinical goal. Coding enclomiphene as a fertility agent may trigger different formulary review pathways than coding it under hypogonadism alone.

A 2023 survey published in Translational Andrology and Urology found that 61% of men prescribed off-label testosterone-stimulating agents paid entirely out of pocket because their insurer denied coverage, while 39% achieved coverage through PA [9]. DC's insurance market, regulated by the Department of Insurance, Securities and Banking, does not mandate coverage of off-label hormonal therapies beyond ACA essential health benefit categories.

For patients whose insurance denies coverage, the compounded 503A route at $90/month remains the most practical alternative. Patients may also request a Letter of Medical Necessity from their prescriber, which sometimes prompts a reconsideration without a formal appeal.

Telehealth Prescribing of Enclomiphene in DC

Telehealth prescribing of enclomiphene is fully legal in DC in 2026. DC law permits prescribers licensed in DC to establish a valid patient-physician relationship via synchronous video visit and issue a prescription for a controlled or non-controlled medication without an in-person physical exam, provided the clinical standard of care is met.

Enclomiphene is not a controlled substance. It carries no DEA scheduling. That makes telehealth prescribing administratively simpler than prescribing testosterone cypionate (Schedule III) or HCG, which carry additional DEA registration requirements for the prescriber and pharmacy.

A typical enclomiphene telehealth pathway in DC runs as follows. The patient completes an online intake with symptom questionnaire. A DC-licensed prescriber (MD, DO, or in some platforms NP or PA operating under collaborative agreement) reviews a recent lab panel including total testosterone, free testosterone, LH, FSH, and a metabolic panel. If the clinical picture is consistent with secondary hypogonadism, the prescriber issues an e-prescription routed to a 503A compounding pharmacy licensed to dispense in DC. The pharmacy ships directly to the patient's DC address.

Lab costs are separate and vary: a male hormone panel at a DC Quest or LabCorp draw site typically costs $75, $150 without insurance or $0, $30 with coverage. HealthRX's own telehealth platform includes lab order coordination as part of the initial consultation.

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency supports laboratory confirmation before initiating any testosterone-axis therapy [10]. Telehealth prescribers operating in DC are expected to meet this standard regardless of the visit modality.

Discount Programs and Savings Options in DC

Several programs can reduce the effective cost of enclomiphene in DC below the $90/month compounded price.

GoodRx and SingleCare. For racemic clomiphene (the generic alternative), GoodRx discounts at DC pharmacies bring the price to $15, $35 per month. GoodRx does not list compounded drugs because they are not assigned a standard NDC; the discount applies only to commercially manufactured products.

Manufacturer and pharmacy savings cards. Compounding pharmacies occasionally offer subscription pricing or multi-month discounts. A 3-month supply purchased upfront may cost $240, $260 versus $270 month-to-month, yielding 6 to 10% savings.

HealthRX Compounded Savings Program. HealthRX coordinates pricing with partner 503A pharmacies so DC patients pay a flat rate with no hidden dispensing fees. The program covers one monthly shipment of compounded enclomiphene, physician follow-up messaging, and a quarterly lab review. Pricing is disclosed at enrollment.

DC's Pharmaceutical Assistance Program. DC's Senior Prescription Drug Program (SPAP) covers residents aged 65 or older who meet income thresholds. Enclomiphene is not specifically listed on the SPAP formulary as of 2026, but beneficiaries may request formulary exception review. This pathway is underutilized and worth exploring for older DC men with hypogonadism.

Research on medication adherence consistently shows that cost is the primary driver of non-adherence in hormonal therapy. A 2022 study in JAMA Internal Medicine found that each $10 increase in monthly out-of-pocket drug cost was associated with a 4% increase in non-adherence at 6 months [11]. Reducing cost barriers in DC matters clinically, not just financially.

Monitoring Requirements and Ongoing Costs After Starting Enclomiphene

Starting enclomiphene is not a one-time expense. Monitoring adds recurring costs that DC patients should budget for.

The Endocrine Society recommends checking serum testosterone, LH, FSH, and hematocrit at 3 months after starting any testosterone-axis therapy, then every 6 to 12 months once stable [3]. For men on enclomiphene, semen analysis at 3 to 6 months is also standard if fertility is a clinical goal, per American Urological Association guidance [10].

Lab costs in DC for a follow-up testosterone panel average $50, $120 cash pay. Semen analysis at a DC andrology lab runs $75, $200. Telehealth follow-up visits on most platforms cost $50, $100 per quarter.

Over 12 months, a DC patient's total annual cost for enclomiphene therapy might look like: $1,080 drug (12 x $90) + $300 labs + $200 visits = approximately $1,580 all-in, without insurance. With DC Medicaid approval, the drug cost drops to near zero and labs may be covered under the medical benefit, bringing total annual cost below $400.

A randomized trial by Wiehle et al. (2014, N=124) confirmed that enclomiphene 12.5 mg and 25 mg maintained testosterone normalization over 3 months with no serious adverse events, supporting the clinical rationale for sustained use [2]. The FDA's review documents for enclomiphene provide additional safety context from the phase III program [5].

What DC Patients Should Do Before Their First Prescription

Before contacting a DC prescriber or telehealth platform, patients should gather three things: a morning fasting testosterone result (drawn between 7, 10 AM), an LH and FSH result from the same draw, and a list of current medications including any supplements that affect the hypothalamic-pituitary-gonadal axis (opioids, anabolic steroids, and certain antifungals are the most common offenders).

Testosterone should be drawn on two separate mornings if the first result is borderline, per Endocrine Society guideline recommendation [3]. A single low result combined with symptoms is sufficient to initiate a clinical conversation but may not satisfy PA requirements for DC Medicaid without a confirmatory sample.

Men with primary hypogonadism (elevated LH/FSH with low testosterone, as in Klinefelter syndrome) are not candidates for enclomiphene; the drug requires an intact pituitary-testicular axis to work [1]. DC prescribers, including telehealth clinicians, are expected to screen for this before prescribing.

Patients with a history of hormone-sensitive cancers, active liver disease, or prior thromboembolic events should discuss the risk-benefit profile in detail with their prescriber. The FDA's adverse event reporting database contains post-marketing data relevant to clomiphene-class drugs [5].